These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2010-020394-17 A Phase 1-2 trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer bad-data
Reported results 2010-020395-28 A Randomized, Double-Blind Phase 2 trial of Exemestane +/- MM-121 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive (ER+) and/or Progesterone Receptor Positive (P... 2014-06-25 due-trials
Listed as ongoing, but also has a completion date 2011-003576-36 A Phase II Randomized Open Label Study of MM-121 in 2015-02-13 bad-data
Not reported 2011-004687-30 NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398 versus 5- Fluorouracil and Leucovorin in Patients with Metastatic Pancreatic Cancer. 2015-11-06 due-trials
Not reported Terminated 2012-003798-25 Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with ‘Traditional’ and ‘Non-Traditional’ HER2 Expressing Carcinomas of the Distal Esophagus, Gast... 2015-05-29 due-trials
Listed as ongoing, but also has a completion date 2014-003159-73 A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician’s Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Pos... 2016-12-31 bad-data
Not reported 2014-003673-42 A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cance... 2018-11-22 due-trials
Not reported Terminated 2014-004572-34 A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus Nab-paclitaxel and Gemcitabine versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer 2018-06-12 due-trials
Ongoing 2015-003086-28 A randomized, open-label, Phase 2 study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic ad... not-yet-due
Not reported Terminated 2017-000565-76 SHERBOC: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic ... 2018-11-26 due-trials